Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
Century Therapeutics announced that its lead asset CNTY-813 has been selected for oral presentations at two major scientific conferences in October 2026. The presentations at EASD and the Breakthrough T1D Congress will highlight preclinical data demonstrating scalable manufacturing and immune evasion capabilities of the iPSC-derived islet therapy.
Key figures
- Drug Name
- CNTY-813
- Crc date
- October 9, 2026
- Easd date
- October 2, 2026
- Ind submission target
- Q4 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.